References
1. From QIAstat-Dx Gastrointestinal Panel 2 (Cat. No. 691412) epidemiology dashboards in QIAsphere Insights, January 2023 – December 2023 for EMEA.
2. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis. 2007;59(3):235-242. doi:10.1016/j.diagmicrobio.2007.04.013
3. Mühlen S, Dersch P. Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli. Front Cell Infect Microbiol. 2020 May 6;10:169. doi: 10.3389/fcimb.2020.00169. PMID: 32435624; PMCID: PMC7218068.
4. European Centre for Disease Prevention and Control Annual Epidemiological Report 2021 – STEC https://www.ecdc.europa.eu/sites/default/files/documents/AER%20STEC%20-%202021.pdf. Accessed February 7, 2024
5. Den Ouden A, Greig DR, Rodwell EV, et al. Escherichia coli encoding Shiga toxin subtype Stx2f causing human infections in England, 2015-2022. J Med Microbiol. 2023;72(6):10.1099/jmm.0.001707. doi:10.1099/jmm.0.001707
6. Engberg J, Vejrum LK, Madsen TV, Nielsen XC. Verification of analytical bacterial spectrum of QIAstat-Dx® GI V2 and Novodiag® Bacterial GE+ V2-0 diagnostic panels. J Antimicrob Chemother. 2021;76(Suppl 3):iii50-iii57. doi:10.1093/jac/dkab242
7. Cointe A, Birgy A, Pascault A, et al. Be aware of Shiga-toxin 2f-producing Escherichia coli: case report and false-negative results with certain rapid molecular panels. Diagn Microbiol Infect Dis. 2020;98(4):115177. doi:10.1016/j.diagmicrobio.2020.115177|
8. Johansen RL, Schouw CH, Madsen TV, Nielsen XC, Engberg J. Epidemiology of gastrointestinal infections: lessons learned from syndromic testing, Region Zealand, Denmark. Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1091-1101. doi: 10.1007/s10096-023-04642-5. Epub 2023 Jul 19. PMID: 37468662; PMCID: PMC10427544. Study performed using QIAstat-Dx Gastrointestinal Panel (V1).
9. Data presented is for the QIAstat-Dx Gastrointestinal Panel 2 (Cat. No. 691412); QIAstat-Dx Gastrointestinal Panel 2 Instructions for Use. QIAGEN, February 2023
10. Castany-Feixas M, Simo S, Garcia-Garcia S, et al. Rapid molecular syndromic testing for aetiological diagnosis of gastrointestinal infections and targeted antimicrobial prescription: experience from a reference paediatric hospital in Spain. Eur J Clin Microbiol Infect Dis. 2021;40(10):2153-2160. Study performed using QIAstat-Dx Gastrointestinal Panel 2.
11. Rogers WS, Westblade LF, Soave R, et al. Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2020;71(7):1693-1700. doi:10.1093/cid/ciz1068
QIAsphere data from connected institutions were used for scientific research purposes only after applying proper de-identification procedures and anonymization techniques, in accordance with HIPAA and GDPR privacy and data protection rules. Data is aggregated from QIAsphere-connected QIAstat-Dx instruments only.
Unless otherwise indicated, data cited pertains to the use of a device from another manufacturer.
Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.
Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).